In a groundbreaking advancement that may redefine transplant medicine, researchers at the Medical University of South Carolina (MUSC) have engineered a novel immunological tool capable of selectively suppressing the immune response responsible for organ rejection. Published in the prestigious journal Frontiers in Immunology, this pioneering work introduces genetically modified regulatory T cells equipped with chimeric anti-HLA antibody receptors (CHARs), which can precisely target and neutralize the antibody-producing B cells that threaten transplanted organs. This innovation promises to circumvent the broad immunosuppression currently necessary, potentially transforming post-transplant care.
Organ transplantation, a lifesaving procedure for thousands annually, confronts a persistent challenge: the recipient’s immune system frequently identifies the donor organ as foreign and mounts an attack against it. While matching human leukocyte antigen (HLA) proteins between donor and recipient ameliorates this issue, complete compatibility is rare due to the vast diversity of HLA variants in the global population—over 40,000 known types. The inability to find ideal matches compels most transplant recipients to rely on systemic immunosuppressants, drugs that indiscriminately dampen immune activity, leaving patients vulnerable to infections and other adverse effects.
The MUSC team, led by Dr. Leonardo Ferreira, assistant professor of Pharmacology and Immunology, approached this problem innovatively by focusing immunosuppression with cellular precision. Unlike conventional immunosuppressants, the group’s approach deploys regulatory T cells (Tregs) re-engineered to seek and suppress only those B cells responsible for producing harmful antibodies against mismatched HLA proteins. These engineered Tregs express a chimeric receptor—a hybrid molecule known as CHAR—that selectively binds to B cells secreting anti-HLA-A2 antibodies, a common problematic variant found in roughly one-third of the global population.
Many patients become pre-sensitized to specific HLA variants like HLA-A2 through previous exposures, including prior transplants, pregnancies, or blood transfusions. This pre-sensitization triggers heightened immune responses, generating large quantities of anti-HLA antibodies that drastically reduce the chances of successful transplantation. The engineered CHAR-Tregs present an elegant solution: by homing in on memory B cells producing anti-HLA-A2 antibodies, Tregs can suppress antibody production without compromising the immune system’s capacity to respond to other threats.
This cell-specific targeting hinges on the unique design of the CHAR—essentially a receptor engineered with the antigen recognition domains of anti-HLA antibodies fused to intracellular signaling components that activate Treg suppressive functions only upon binding the target B cells. Upon recognizing and binding the offending B cells, CHAR-Tregs become activated, releasing immunoregulatory signals that quell the antibody-mediated attack against donor organs while maintaining overall immune vigilance.
To test the real-world potential of their innovation, Dr. Ferreira’s team obtained samples from pre-sensitized kidney dialysis patients with histories of organ rejection from University Hospital La Paz in Madrid, Spain, under collaboration with Dr. Eduardo Lopez-Collazo’s laboratory. The results were remarkable: exposure to CHAR-Tregs led to a dramatic reduction in anti-HLA-A2 antibody levels produced by patients’ B cells, demonstrating that these engineered cells can effectively modulate immune responses even in highly sensitized individuals.
This level of specificity in immune modulation is unprecedented in transplant medicine. While previous attempts at cellular immunotherapy have focused primarily on cancer or infectious diseases, applying this technique to prevent organ rejection addresses a long-standing unmet need. By constraining immunosuppression to unwanted immune responses, patients may avoid the risks associated with generalized immune suppression such as opportunistic infections, malignancies, and drug toxicity.
Importantly, these findings open avenues for helping patients traditionally considered poor candidates for transplantation due to pre-sensitization. For such individuals, the challenge of finding compatible organs is compounded by immune memory against common donor antigens. The CHAR-Treg platform could reset immune tolerance in these patients, broadening transplant eligibility and improving long-term graft survival.
The conceptual foundation draws on intricate understanding of immune system balance. While B cells orchestrate antibody production to defend against pathogens, regulatory T cells function as immune system moderators, restraining excessive or misdirected responses. The breakthrough lies in coupling these two elements in a synthetic yet physiologically harmonious system—a biological “smart missile” that delivers suppression exclusively where it is needed.
Dr. Ferreira describes this novel immunotherapy as analogous to applying the brakes selectively in a car rather than slamming on the brakes for all wheels at once. This control minimizes collateral damage to the immune system’s protective effects. The preclinical data rally optimism that this balance between immune activation and inhibition can be achieved in complex human immune environments.
Looking ahead, the team envisions translating these findings into clinical applications, with the potential to develop personalized cell therapies tuned to individual patients’ immunological profiles and sensitization histories. Such therapies could revolutionize post-transplant management, improving graft longevity and patient quality of life while reducing the need for lifelong pharmacologic immunosuppression.
Apart from transplantation, this approach heralds a new paradigm for treating autoimmune and antibody-mediated diseases by exploiting chimeric antigen receptor technologies beyond oncology. The adaptation of CAR-based targeting to regulatory T cells may inaugurate a versatile platform for precise immune modulation, tailoring treatments to complex immunological challenges.
This groundbreaking work represents a remarkable confluence of immunology, genetic engineering, and translational medicine. With over 50,000 organ transplants performed annually in the U.S. alone, innovations like CHAR-Tregs could drastically reduce the burden of rejection and transform lives worldwide. As the research progresses toward human trials, the medical community eagerly anticipates a new era where the immune system can be fine-tuned with surgical precision to promote healing and tolerance.
Subject of Research: Human tissue samples
Article Title: Chimeric anti-HLA antibody receptor engineered human regulatory T cells suppress alloantigen-specific B cells from pre-sensitized transplant recipients.
News Publication Date: 15-Aug-2025
Web References: http://dx.doi.org/10.3389/fimmu.2025.1601385
Image Credits: Medical University of South Carolina, Photo by Clif Rhodes
Keywords: organ transplantation, immune rejection, regulatory T cells, chimeric antibody receptor, HLA-A2, pre-sensitization, immunosuppression, engineered cell therapy, antibody-producing B cells, molecular immunology, transplant immunology, precision immunotherapy
